{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gleevec&page=4", "query": { "intervention": "Gleevec", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 351, "total_pages": 36, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gleevec&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gleevec&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T00:16:43.275Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01083589", "title": "Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Imatinib Mesylate", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2005-01", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2012-01-11", "last_synced_at": "2026-10-20T00:16:43.275Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01083589" }, { "nct_id": "NCT00080678", "title": "Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Cancer", "Prostate Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Imatinib Mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 116, "start_date": "2003-05", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2012-10-12", "last_synced_at": "2026-10-20T00:16:43.275Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00080678" }, { "nct_id": "NCT00519090", "title": "Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelogenous Leukemia" ], "interventions": [ { "name": "Imatinib", "type": "DRUG" }, { "name": "Nilotinib (AMN107)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2007-10", "completion_date": "2008-10", "has_results": true, "last_update_posted_date": "2011-11-07", "last_synced_at": "2026-10-20T00:16:43.275Z", "location_count": 36, "location_summary": "Tucson, Arizona • Anaheim, California • Baldwin Park, California + 32 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Fontana", "state": "California" }, { "city": "Hayward", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00519090" }, { "nct_id": "NCT01781975", "title": "Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type I", "Diabetes Mellitus, Insulin-Dependent, 1", "Type 1 Diabetes Mellitus", "Insulin-Dependent Diabetes Mellitus 1", "IDDM" ], "interventions": [ { "name": "Imatinib Mesylate", "type": "DRUG" }, { "name": "Placebo (For imatinib mesylate)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 67, "start_date": "2014-01", "completion_date": "2018-05", "has_results": true, "last_update_posted_date": "2020-02-11", "last_synced_at": "2026-10-20T00:16:43.275Z", "location_count": 8, "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01781975" }, { "nct_id": "NCT01188889", "title": "RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2013-09", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2015-05-15", "last_synced_at": "2026-10-20T00:16:43.275Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01188889" }, { "nct_id": "NCT00021229", "title": "Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "local irradiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 85, "start_date": "2001-05", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2014-07-31", "last_synced_at": "2026-10-20T00:16:43.275Z", "location_count": 10, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00021229" }, { "nct_id": "NCT03112603", "title": "A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Graft-versus-host Disease (GVHD)" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Extracorporeal photopheresis (ECP)", "type": "DRUG" }, { "name": "Low-dose methotrexate (MTX)", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Pentostatin", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 330, "start_date": "2017-06-29", "completion_date": "2022-12-15", "has_results": true, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-10-20T00:16:43.275Z", "location_count": 38, "location_summary": "Tucson, Arizona • Duarte, California • La Jolla, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03112603" }, { "nct_id": "NCT05489237", "title": "First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Neoplasms", "Gastrointestinal Stromal Tumor (GIST)", "Digestive System Disease", "Gastrointestinal Diseases", "Metastatic Cancer" ], "interventions": [ { "name": "IDRX-42", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IDRX, Inc., a wholly owned subsidiary of GSK, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 276, "start_date": "2022-08-03", "completion_date": "2027-03-26", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-20T00:16:43.275Z", "location_count": 8, "location_summary": "Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 5 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05489237" }, { "nct_id": "NCT00015834", "title": "STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Blastic Phase Chronic Myelogenous Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Relapsing Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2001-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-10-20T00:16:43.275Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00015834" }, { "nct_id": "NCT03673501", "title": "A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastrointestinal Stromal Tumors" ], "interventions": [ { "name": "Ripretinib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Deciphera Pharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 453, "start_date": "2019-02-08", "completion_date": "2027-12", "has_results": true, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-20T00:16:43.275Z", "location_count": 43, "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 38 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03673501" } ] }